pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
Ligelizumab
Phase 3 · mab · Chronic Spontaneous Urticaria
Ligelizumab for Chronic Spontaneous Urticaria is a Phase 3 program (mab) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CQGE031C2303
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 3
- Modality
- mab
- Indication
- Chronic Spontaneous Urticaria
- Status
- completed
- Trials
- 1